A recent retrospective study compared the efficacies of administration of an SGLT2 inhibitor or a DPP4 inhibitor for 24 weeks in Japanese patients with T2DM and biopsy-confirmed NAFLD.39 Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.